This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

James M. Brophy, MD, FRCPC, PhD

JAMA. 2005;294:2633-2635. Published online October 20, 2005 (doi:10.1001/jama.294.20.jed50074).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Peroxisome proliferator–activated receptors (PPARs) are nuclear cell transcription factors with isoform agonists that exhibit clinical benefit. The PPAR- agonists increase insulin sensitivity, explaining the antidiabetic action of the thiazolidinediones rosiglitazone and pioglitazone. PPAR- agonists, including the fibrates, increase fatty acid oxidation, leading to a decrease in plasma triglycerides and a modest increase in high-density lipoprotein cholesterol. Muraglitazar is the first dual-PPAR agonist to be considered for general marketing both as monotherapy and combined therapy by the US Food and Drug Administration (FDA). Given the emerging epidemic of type 2 diabetes, it is easy to understand the enthusiasm for this new class of drugs. Tight glycemic control reduces diabetic microvascular complications, although both old¹ and new² studies have failed to convincingly show decreased macrovascular complications of stroke, cardiac disease, and peripheral vascular disease.

On September 9, 2005, an FDA advisory committee reviewed muraglitazar’s efficacy and . . . [Full Text of this Article]

Author Affiliations: Department of Medicine, McGill University Health Centre, McGill University, Montréal, Quebec.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Steven E. Nissen, Kathy Wolski, and Eric J. Topol
JAMA. 2005;294(20):2581-2586.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Better regulation of industry-sponsored clinical trials is long overdue.
Wynia and Boren
J Law Med Ethics 2009;37:410-419.
 

Antidiabetic Action of Bezafibrate in a Large Observational Database
Flory et al.
Diabetes Care 2009;32:547-551.
ABSTRACT | FULL TEXT  

Accessing FDA Approval Packages and Briefing Documents
Ohmer et al.
The Annals of Pharmacotherapy 2007;41:2071-2072.
FULL TEXT  

Detection and reporting of drug-induced proarrhythmias: room for improvement
Darpo
Europace 2007;9:iv23-iv36.
ABSTRACT | FULL TEXT  

The Molecular Mechanisms Underlying the Proinflammatory Actions of Thiazolidinediones in Human Macrophages
Hall and McDonnell
Mol. Endocrinol. 2007;21:1756-1768.
ABSTRACT | FULL TEXT  

Evolution of Peroxisome Proliferator-Activated Receptor Agonists
Chang et al.
The Annals of Pharmacotherapy 2007;41:973-983.
ABSTRACT | FULL TEXT  

Is Muraglitazar Safe for Patients with Type 2 Diabetes?
JWatch General 2005;2005:3-3.
FULL TEXT